1591TiPIFCT-1701 DICIPLE: A randomized phase III trial comparing continuation nivolumab-Ipilimumab doublet immunotherapy until progression versus observation in patients with PDL1-positive stage IV non-small cell lung cancer (NSCLC) after nivolumab-ipilimumab induction treatment

Abstract Background We raise the hypothesis that a STOP and GO strategy with induction by double immunotherapy Nivolumab + Ipilimumab combination during 6 months, followed by observation in patients with disease control (DC) at 6 months, would not be inferior to immunotherapy combination continuatio...

Ausführliche Beschreibung

Bibliographische Detailangaben

Veröffentlicht in:	Annals of oncology 2019-10, Vol.30 (Supplement_5)
Hauptverfasser:	Zalcman, G, Toffart, A C, Madroszyk Flandin, A-C, Molinier, O, Dayen, C, Egenod, T, Dixmier, A, Giroux Leprieur, E, Masson, P, Cloarec, N, Thibonnier, L, Favier, L, Debieuvre, D, Mazieres, J, Van Hulst, S, Pichon, E, Amour, E, Morin, F, Souquet, P-J
Format:	Artikel
Sprache:	eng
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!